Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
Quite apart from the good news regarding adjuvant treatment of breast cancer, I was delighted to learn of the " Off Patent Drugs Bill, which had its first reading in the House of Commons on 24 June this year. The bill is designed to put a legal duty on the government to seek licences for drugs in cases where a drug company is unlikely to do so, so that off patent treatments are approved for use on the NHS."
Such measures will go some way to offset the perversities of the 'Lyrica and Lucentis lunacy'. Is it possible that the Bill be extended to include a duty on the NHS to seek MHRA authorisation for unlicensed and off-label indications ( at least those identified as being cost-effective by NICE ) to comply with recent EU legal restriction ?